Use of an anti-ALK antibody in the characterization of anaplastic large- cell lymphoma of childhood

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  Hutchison, R E ^a,k   Banki, K ^a   Shuster, J J ^b   Barrett, D ^a   Dieck, C ^a   Berard, C W ^c   Murphy, S B ^d   Link, M P ^e   Pick, T E ^f   Laver, J ^g   Schwenn, M ^h   Mathew, P ^i,j   Morris, S W ^c  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f BROOKE ARMY MEDICAL CENTER   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ MEDICAL COLLEGE OF OHIO   (United States)

^j Pediatric Oncology Group   (United States)

^k Department of Clinical Pathology ^*  (United States)

more..

Author keywords

adolescence; ALK antigen; anaplasia; anaplastic large cell lymphoma; CD30 antigen; child; diagnosis; Ki 1 large cell lymphoma; non Hodgkin's lymphoma

Indexed keywords

PROTEIN TYROSINE KINASE;

ANAPLASTIC CARCINOMA; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION 2; CHROMOSOME TRANSLOCATION 5; CLINICAL ARTICLE; CONFERENCE PAPER; HUMAN; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 8244249458     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.S37     Document Type: Conference Paper

References (61)

1. Poplack DG, Kun LE, Magrath IT et al. Leukemias and lymphomas of childhood. In DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott 1994; 1792.
2. Reiter A, Schrappe M, Parwaresch R et al. Non-Hodgkin's lymphomas of childhood and adolescence: Results of a treatment stratified for biologic subtypes and stage - a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol 1995; 13: 359-72.
3. Murphy SB. Pediatric lymphomas: Recent advances and commentary on Ki-1-positive anaplastic large-cell lymphomas of childhood. Ann Oncol 1994; 5 (Suppl 1): S31-3.
4. Murphy SB, Fairclough DL, Hutchison RE et al. Non-Hodgkin's lymphomas of childhood: An analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol 1989; 7: 186-93.
5. Kjeldsberg CR, Wilson JF, Berard CW. Non-Hodgkin's lymphoma in children. Hum Pathol 1983; 14: 612-27.
6. Wilson JF, Jenkin RD, Anderson JR et al. Studies on the pathology of non-Hodgkin's lymphoma of childhood. I. The role of routine histopathology as a prognostic factor: A report from the Children's Cancer Study Group. Cancer 1984; 53: 1695-704.
7. Nathwani BN, Griffith RC, Kelly DR et al. A morphologic study of childhood lymphoma of the diffuse 'histiocytic' type: The Pediatric Oncology Group experience. Cancer 1987; 59: 1138-42.
8. Hutchison RE, Fairclough DL, Holt H et al. Clinical significance of histology and immunophenotype in childhood diffuse large cell lymphoma. Am J Clin Pathol 1991; 95: 787-93.
9. Writing committee. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112-35.
10. Stansfeld AG, Diebold J, Noel H et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-3.
11. Schnitzer B, Roth MS, Hyder DM et al. Ki-1 lymphomas in children. Cancer 1988; 61: 1213-21.
12. Delsol G, Al Saati T, Gatter KC et al. Coexpression of epithelial membrane antigen (EMA). Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas: Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988; 130: 59-70.
13. +) in childhood. Med Pediatr Oncol 1993; 21: 402-10.
14. + large-cell non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 895-8.
15. Stein H, Mason DY, Gerdes J et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-58.
16. Suchi T, Lennert K, Tu LY et al. Histopathology and immunohistochemistry of peripheral T-cell lymphomas: A proposal for their classification. J Clin Pathol 1987; 40: 995-1015.
17. Chan JK, Ng CS, Hui PK et al. Anaplastic large cell Ki-1 lymphoma. Delineation of two morphological types. Histopathology 1989; 15: 11-34.
18. + T-cell lymphoma. Am J Surg Pathol 1993; 17: 859-68.
19. Chott A, Kaserer K, Augustin I et al. Ki-1-positive large cell lymphoma: A clinicopathologic study of 41 cases. Am J Surg Pathol 1990; 14: 439-48.
20. + with a high content of reactive histiocytes). Histopathology 1990; 16: 383-91.
21. Kadin ME. Primary Ki-1-positive anaplastic large-cell lymphoma: A distinct clinicopathologic entity. Ann Oncol 1994; 5 (suppl 1): S25-30.
22. Mann KP, Hall B, Kamino H et al. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol 1995; 19:407-16.
23. Piris M, Brown DC, Gatter KC et al. CD30 expression in non-Hodgkin's lymphoma. Histopathology 1990; 17: 211-8.
24. Pallesen G. The diagnostic significance of the CD30 (Ki-1) antigen. Histopathology 1990; 16: 409-13.
25. Kinney MC, Greer JP, Glick AD et al. Anaplastic large-cell Ki-1 malignant lymphomas: Recognition, biological and clinical implications. Pathol Ann 1991; 26 (pt 1): 1-24.
26. Schwarting R, Gerdes J, Durkop H et al. BER-H2: A new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 1989; 74: 1678-89.
27. Agnarsson BA, Kadin ME. Ki-1-positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 1988; 12: 264-74.
28. Weisenburger DD, Gordon BG, Vose JM et al. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma. Blood 1996; 87: 3860-8.
29. Borisch B, Gatter KC, Tobler A et al. Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol 1992; 98: 312-8.
30. Borisch B, Fey MF, Tobler A et al. Grosszellige anaplastische Lymphome bei Immunsuppression [Large-cell anaplastic lymphomas in the immunocompromised host]. Verh Dtsch Ges Pathol 1991; 75: 171-4.
31. Herbst H, Stein H. Tumor viruses in CD30-positive anaplastic large cell lymphomas. Leuk Lymph 1993; 9: 321-8.
32. + lymphomas. Am J Clin Pathol 1993; 99: 289-97.
33. + malignant lymphomas. Crit Rev Oncog 1993; 4: 191-239.
34. Carbone A, Tirelli U, Gloghini A et al. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993; 11: 1674-81.
35. Carbone A, Gloghini A, Volpe R et al. (Italian Cooperative Group on AIDS and Tumors). High frequency of Epstein-Barr virus latent membrane protein-1 expression in acquired immunodeficiency syndrome-related Ki-1 (CD30)-positive anaplastic large-cell lymphomas. Am J Clin Pathol 1994; 101: 768-72.
36. Anagnostopoulos I, Hummel M, Kaudewitz P et al. Detection of HTLV-I proviral sequences in CD30-positive large cell cutaneous T-cell lymphomas. Am J Pathol 1990; 137:1317-22.
37. Tsuji M, Kobashi A, Hashimoto K et al. A case of adult T-cell leukemia/lymphoma, histologically presenting CD30-positive large cell lymphoma. Acta Pathol Jpn 1992; 42: 512-7.
38. Abbondanzo SL, Sato N, Straus SE et al. Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologie correlations. Am J Clin Pathol 1990; 93: 698-702.
39. Mason DY, Bastard C, Rimokh R et al. CD30-positive large cell lymphomas (Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol 1990; 74: 161-8.
40. Le Beau MM, Bitter MA, Larson RA et al. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1-positive anaplastic large cell lymphoma. Leukemia 1989; 3: 866-70.
41. Kaneko Y, Frizzera G, Edamura S et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 1989; 73: 806-13.
42. Rimokh R, Magaud JP, Berger F et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma'). Br J Haematol 1989; 71: 31-6.
43. Bitter MA, Franklin WA, Larson RA et al. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 1990; 14: 305-16.
44. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281-4. [Published erratum appeared in Science 1995; 267: 316-7].
45. + anaplastic large-cell lymphomas. in other non-Hodgkin's lymphomas of T-cell phenotype. and in Hodgkin's disease. Blood 1995; 86: 2321-8.
46. Elmberger PG, Lozano MD, Weisenburger DD et al. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 1995; 86: 3517-21.
47. Lamant L, Meggetto F, Al Saati T et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996; 87: 284-91.
48. Herbst H, Anagnostopoulos J, Heinze B et al. ALK gene products in anaplastic large cell lymphomas and Hodgkin's disease. Blood 1995; 86: 1694-700.
49. Downing JR, Shurtleff SA, Zielenska M et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 1995; 85: 3416-22.
50. Waggott W, Lo YD, Bastard C et al. Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma. Br J Haematol 1995; 89: 905-7.
51. Xerri L, Parc P, Hassoun J et al. Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease. J Pathol 1996; 178: 128-32.
52. Sandlund JT, Pui CH, Roberts WM et al. Clinicopathologic features and treatment outcome of children with large-cell lymphoma and the t(2;5)(p23;q35). Blood 1994; 84: 2467-71.
53. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity. Blood 1995; 86: 1954-60.
54. Dirks WG, Zaborski M, Jaeger K et al. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: Absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 1996; 10: 142-9.
55. Shiota M, Fujimoto J, Takenaga M et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84: 3648-52.
56. Hutchison RE, Berard CW, Shuster JJ et al. B-cell lineage confers a favorable outcome among children and adolescents with large-cell lymphoma: A Pediatric Oncology Group study. J Clin Oncol 1995; 13: 2023-32.
57. Mathew P, Morris SW, Kane JR et al. Localization of the murine homolog of the anaplastic lymphoma kinase (ALK) gene on mouse chromosome 17. Cytogenet & Cell Genet 1995; 70: 143-4.
58. Morris SW, Naeve C, Mathew P et al. ALK. the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene (in press).
59. C. STATXACT. Cambridge, MA: Cytel Software 1992.
60. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
61. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.